Benoit Van den Eynde's group page
Old Road Campus Research Building
Benoit Van den Eynde
Professor of Tumour Immunology
I am an expert in tumour immunology (MD, PhD) and I am currently a Member of the Ludwig Institute for Cancer Research and Director of the de Duve Institute, Belgium. I am also Full Professor of Immunology at the Université catholique de Louvain in Brussels and I train young scientists, including PhD students, medical students and postdoctoral Fellows from all over the world. I serve as member of several national and international scientific committees and editorial boards, and I am a full member of the Belgian Royal Academy of Medicine.
I initially identified, together with Thierry Boon, the first tumour rejection antigen naturally expressed by mouse tumours and recognised by CD8 T lymphocytes. I subsequently identified a number of human tumour antigens recognised by CD8 T lymphocytes and I studied their processing, i.e. how they are produced by the cell. This led to the discovery of peptide splicing by the proteasome and of novel proteasome subtypes. I also described how tumours resist immune rejection by degrading tryptophan, through the expression of indoleamine dioxygenase (IDO) or tryptophan dioxygenase (TDO).
I am co-founder of iTeos Therapeutics, a biotechnology company based in Gosselies (Belgium) launched in 2012 as a spin-off of Ludwig Cancer Research. Its activity consists in developing small molecule immunomodulators for cancer treatment. Its first compound, an IDO inhibitor, is at the stage of clinical testing in cancer patients.
In 2016, I started a second group at Ludwig Oxford, to develop synergies in the tumour immunology landscape, focusing on cancer vaccines. I am also Professor of Tumour Immunology at the University of Oxford.
I have published more than 175 scientific papers and books and given more than 150 invited lectures at international meetings. My work has been cited more than 15,000 times in the scientific literature.
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.
Uyttenhove C. et al, (2003), Nat Med, 9, 1269 - 1274
An antigenic peptide produced by reverse splicing and double asparagine deamidation.
Dalet A. et al, (2011), Proc Natl Acad Sci U S A, 108, E323 - E331
An antigen produced by splicing of noncontiguous peptides in the reverse order.
Warren EH. et al, (2006), Science, 313, 1444 - 1447
Production of an antigenic peptide by insulin-degrading enzyme.
Parmentier N. et al, (2010), Nat Immunol, 11, 449 - 454
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase.
Pilotte L. et al, (2012), Proc Natl Acad Sci U S A, 109, 2497 - 2502
Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC.
Leung CSK. and Van den Eynde BJ., (2022), Cancer Cell
New Insights into the Mechanisms of Proteasome-Mediated Peptide Splicing Learned from Comparing Splicing Efficiency by Different Proteasome Subtypes.
Ferrari V. et al, (2022), Journal of immunology (Baltimore, Md. : 1950)